Description of FOXO4-DRI

FOXO4-DRI is a synthetic peptide designed as a retro-inverso analog of the transcription factor FOXO4, in which naturally occurring L-amino acids are substituted with their D-enantiomers. This structural modification significantly extends its half-life and enhances resistance to proteolytic degradation, thereby enabling prolonged biological activity in vivo. The mechanism of action of FOXO4-DRI lies in its ability to competitively interfere with the binding of endogenous FOXO4 to the p53 protein—a central regulator of the cell cycle and apoptosis. This FOXO4–p53 interaction is essential for maintaining the viability of senescent cells. By inhibiting this interaction, FOXO4-DRI allows reactivation of the apoptotic pathway in non-proliferative senescent cells, leading to their selective elimination without damaging healthy tissue.

Preclinical studies in animal models have yielded several noteworthy findings. In addition to a significant reduction in senescent cell burden within tissues treated with FOXO4-DRI, restoration of functional integrity was observed in organs such as the kidneys, liver, and skin. Interestingly, aged mice exhibited a re-emergence of several youthful phenotypic traits following treatment—including increased physical activity, improved cognitive performance, and enhanced fur density.

Further experiments have demonstrated that the peptide is capable of suppressing the activity of pro-inflammatory and fibrotic factors characteristic of the senescence-associated secretory phenotype (SASP), thereby contributing to the restoration of damaged tissue microenvironments. A significant finding is its effect in pathological scarring models, such as keloids, where it promoted apoptosis in resistant fibroblasts and reduced cell proliferation during the G0/G1 phase of the cell cycle. These findings underscore its potential as a senolytic agent with therapeutic applications in degenerative diseases, dermatology, and regenerative medicine. The following sections will provide a detailed overview of research findings across these domains.

[2], [4]

Definition of Retro-Inverso Peptides

Retro-inverso peptides (also referred to as D-retro-inverso or DRI peptides) are specially engineered molecules in which the amino acid sequence is reversed and composed of D-amino acids, which are mirror images of the naturally occurring L-amino acids. These peptides mimic the spatial conformation of the parent (native) molecules while exhibiting significantly enhanced resistance to enzymatic degradation, thereby enabling prolonged biological activity and reduced immunogenicity. Due to these properties, they represent promising candidates for the development of more stable and efficacious therapeutics, particularly when targeting protein–protein interactions. Although the retro-inverso approach may fail to accurately reproduce biological function in the context of helical structures (e.g., p53 or HIV-1 proteins), certain exceptions—such as the binding of a p53-derived retro-inverso peptide to its regulator MDM2—demonstrate that well-designed D-peptides can, in specific cases, effectively mimic the function of the original peptide.

[3]

Research Confirmed Effects

1. FOX04-DRI in the Context of Aging and Cellular Senescence

The relationship between the transcription factor FOXO4 and aging processes is highly complex; however, research suggests that this molecule plays a pivotal role in regulating longevity, cellular stress resistance, and genomic integrity. FOXO4 is a member of the broader FOXO protein family, which has preserved both structural and functional characteristics across various animal species and has long been associated with pathways influencing aging. A key aspect of FOXO4's function lies in its involvement in insulin and insulin-like growth factor (IGF) signaling pathways, which regulate metabolism, cell cycle progression, and apoptosis. Studies in the model organism Caenorhabditis elegans have demonstrated that different FOXO isoforms—particularly DAF-16A—exert a significant influence on lifespan extension by activating or repressing specific genes such as gst-20 and srr-4, which either promote or inhibit longevity-associated mechanisms.

Particularly noteworthy is that FOXO4 influences not only lifespan but also the quality of aging through its interaction with the protein p53—commonly referred to as the "guardian of the genome." This interaction regulates whether cells remain in a senescent, metabolically inactive state or undergo programmed cell death (apoptosis). This specific property has become the focus of numerous research strategies, such as the development of senolytic agents like FOXO4-DRI, which selectively disrupt the FOXO4–p53 interaction, thereby enabling the targeted elimination of dysfunctional cells. These findings not only provide deeper insight into the molecular foundations of aging but also open promising avenues for interventions aimed at extending healthspan and preventing age-associated diseases.

Studies show that the transcription factor FOXO4 plays a protective role in senescent cells by maintaining the protein p53 in a sequestrated state within nuclear structures, thereby inhibiting its ability to initiate apoptosis. While this mechanism prevents premature cell death, it simultaneously promotes the accumulation of damaged and dysfunctional cells, which disrupt tissue homeostasis and contribute to the progression of age-related diseases. The synthetic peptide FOX04-DRI selectively disrupts this interaction, thereby restoring the apoptotic activity of p53 and leading to the elimination of senescent cells. This process, referred to as therapeutic rejuvenation, improves tissue functional status analogously to the biological principle where the removal of dysfunctional structures allows for more efficient resource utilization by healthy cells. The elimination strategy targeting senescent cells thus represents a promising approach in the prevention and treatment of various pathologies, including cancer, cardiovascular, and neurodegenerative diseases, by targeting the very biological foundation of aging.

[5], [6], [7]

2. FOXO4-DRI and Insulin Signaling

Transcription factors of the FOXO family – specifically FOXO1, FOXO3, FOXO4, and FOXO6 – are key mediators of insulin and IGF signaling, participating in the regulation of a wide range of cellular processes, including metabolism, cell growth and differentiation, response to oxidative stress, autophagy, senescence, and aging-related processes. Experimental models demonstrate that FOXO proteins mediate the inhibitory effects of insulin/IGF on target genes and are essential for maintaining metabolic homeostasis. Mutations in the genes encoding these proteins, as well as their abnormal expression, are associated with the pathogenesis of several diseases, including type 2 diabetes, insulin resistance, cancer, and neurodegenerative disorders.

FOXO6, as the most evolutionarily divergent member of this group, exhibits tissue-specific expression, particularly in liver, muscle, and neural tissues, and its effects on insulin signaling significantly differ from the other isoforms. Abnormalities in the expression or function of FOXO6 have been identified as a pathophysiological basis for the development of fasting hyperglycemia and hyperlipidemia, which are serious metabolic complications in diabetic patients. In this context, therapeutic strategies aimed at the selective inhibition of FOXO proteins – including the use of peptide analogs such as FOXO4-DRI – appear to be a promising approach for modulating metabolic pathways, with the potential to alleviate diabetes-related complications.

[8]

3. FOXO4-DRI and Heart Disease

With advancing age, there is a decline in proteasome activity in cardiac tissue, which represents a significant mechanism contributing to the increased susceptibility of older organisms to cardiovascular diseases. Proteasomes play a crucial role in the degradation of oxidized and ubiquitinated proteins, thus maintaining protein homeostasis and ensuring an adequate cellular stress response. Experimental studies in rat models have shown that the activity of the 20S proteasome decreases with age, which is accompanied not only by a reduction in its quantity but also by changes in the composition and structure of its subunits. These changes lead to the accumulation of damaged proteins in myocytes, thereby reducing their ability to adapt to physiological stress and increasing the risk of heart disease in old age.

FOXO transcription factors, particularly FOXO4, play a crucial role in regulating cellular mechanisms associated with longevity and tissue protection against damage. In addition to regulating insulin and insulin-like growth factor signaling pathways, these factors are also involved in the control of autophagy and proteasome activity – key mechanisms responsible for the degradation of damaged or oxidized proteins. Increased FOXO4 expression correlates with enhanced proteasomal activity, leading to a reduction in the accumulation of damaged proteins, particularly in cardiovascular tissue. These findings suggest that therapeutic modulation of FOXO4 activity, such as through the use of the synthetic peptide FOXO4-DRI, could bolster the heart's natural protective mechanisms and mitigate degenerative changes associated with aging.

[9], [10]

4. FOXO4-DRI and Neurodegenerative Diseases

Age-related changes in cognitive function have a multifactorial origin, with proteasomal dysfunction potentially playing a significant role. This system, responsible for the degradation of damaged and unnecessary proteins through ubiquitin-mediated mechanisms, regulates numerous fundamental cellular processes. Disruption of its function has been identified in several neurodegenerative diseases, including Alzheimer's, Parkinson's, Huntington's, and prion diseases, as well as in amyotrophic lateral sclerosis (ALS). While it has not been conclusively established whether this dysfunction is a cause or consequence of the pathological processes, growing evidence suggests that reduced proteasomal activity may contribute to the accumulation of toxic protein aggregates and the progression of neurodegeneration. These insights open new avenues for research into pathogenesis and the development of targeted therapies based on the modulation of proteasomal function.

FOXO transcription factors play a crucial role in the regulation of processes related to aging and longevity, with increasing evidence suggesting their significance in the pathogenesis of neurodegenerative diseases (NDDs). These diseases are characterized by progressive neuronal damage and worsening neurological function, with effective therapeutic targets remaining limited. FOXO proteins undergo various post-translational modifications (phosphorylation, acetylation, ubiquitination, methylation, glycosylation) that influence their biological function in the central nervous system. Research indicates that FOXO factors may have both protective and detrimental effects in the context of neurodegeneration, depending on how they are regulated. A promising direction appears to be the study of the therapeutic potential of exogenous forms, such as FOX04-DRI, which could slow the progression of neurodegenerative disorders. In this context, there is an emphasis on the need for a deeper understanding of the functions of FOXO in the nervous system, which could lead to the development of targeted therapies for these severe diseases.

[11], [12]

References

1. W. Liu, Y. Song, J. Wang, H. Xiao, Y. Zhang, and B. Luo, “Dysregulation of FOXO transcription factors in Epstein-Barr virus-associated gastric carcinoma,” Virus Res., p. 197808, Nov. 2019.
2. Yu-Xiang Kong, Zhi-Shuai Li, Yuan-Bo Liu, Bo Pan, Xin Fu, Ran Xiao, „FOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation“, 2025.
3. Chong Li, Marzena Pazgier, Jing Li, Changqing Li, Min Liu , Guozhang Zou, Zhenyu Li , Jiandong Chen , Sergey G. Tarasov , Wei-Yue Lu, „Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry“, Volume 285, Issue 25, 18 June 2010, Pages 19572-19581.
4. Baar, Marjolein P, et al. “Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis in Response to Chemotoxicity and Aging.” Cell, vol. 169, no. 1, 2017, pp. 132-147.e16, www.ncbi.nlm.nih.gov/pubmed/28340339, 10.1016/j.cell.2017.02.031.
5. A. T.-Y. Chen et al., “Longevity Genes Revealed by Integrative Analysis of Isoform-Specific daf-16/FoxO Mutants of Caenorhabditis elegans,” Genetics, vol. 201, no. 2, pp. 613–629, Oct. 2015.
6. P. Krimpenfort and A. Berns, “Rejuvenation by Therapeutic Elimination of Senescent Cells,” Cell, vol. 169, no. 1, pp. 3–5, 23 2017.
7. “Senescence and aging: Causes, consequences, and therapeutic avenues | JCB.” [Online]. Available: http://jcb.rupress.org/content/217/1/65. [Accessed: 17-Nov-2019].
8. S. Lee and H. H. Dong, “FoxO integration of insulin signaling with glucose and lipid metabolism,” J. Endocrinol., vol. 233, no. 2, pp. R67–R79, 2017.
9. A.-L. Bulteau, L. I. Szweda, and B. Friguet, “Age-dependent declines in proteasome activity in the heart,” Arch. Biochem. Biophys., vol. 397, no. 2, pp. 298–304, Jan. 2002.
10. G. Murtaza, A. K. Khan, R. Rashid, S. Muneer, S. M. F. Hasan, and J. Chen, “FOXO Transcriptional Factors and Long-Term Living,” Oxid. Med. Cell. Longev., vol. 2017, 2017.
11. A. Ciechanover and P. Brundin, “The ubiquitin proteasome system in neurodegenerative diseases: sometimes the chicken, sometimes the egg,” Neuron, vol. 40, no. 2, pp. 427–446, Oct. 2003.
12. W. Hu et al., “Roles of forkhead box O (FoxO) transcription factors in neurodegenerative diseases: A panoramic view,” Prog. Neurobiol., vol. 181, p. 101645, Oct. 2019.